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The problem that we face as a nation is the increasing cases of opiate overdoses (CDC, 2019).  
Regulations vary across state lines regarding patient needs and prescribing regulations.  The 
current study addresses closing the gaps in opioid use disorder.  The overarching research 
question for this study is—How are Narcan policies related to the drug’s utilization?  Other 
questions in this study will be explored through analysis of national claims data.  The study 
population consist of beneficiaries who have received a prescription for Narcan in 2016.  The 
data includes Narcan prescriptions across state lines as well as the Narcan access law.  Using the 
MarketScan Commercial Database we look at patient claims from states that do not have a 
Narcan access law and states with a Narcan access law.  The study included a total of 3,756,833 
prescriptions for naloxone and opioids (14,210, 0.38%), naloxone only (1660, 0.04%), and 
opioids only (3,740,963, 99.6%) provided to privately insured individuals in 2016.  In total, 7448 
Naloxone prescriptions by State Policy Status were dispensed in 2016.  The odds of receiving a 
Naloxone prescription in access law states presented 40% greater than the states without the 
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access law in 2016.  This study will add to the literature concerning the misuse of prescription 
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CHAPTER I INTRODUCTION 
 
1.1. Background and Need 
In the last two decades, there has been a rise in misuse of prescription and illicit opioids 
(Hodge, Gulinson & Barraza, 2019).  During this same time, across the United States, there has 
been an increase in opioid-induced and opioid-related deaths (Centers for Disease and Control 
and Prevention [CDC], 2019).  Commonly utilized opiates include Vicodin, oxytocin, and 
heroin.  The United States continues to develop programs to reverse opiate overdoses and 
educate individuals on overdose prevention.  Narcan, also known as Naloxone, is a highly 
effective opiate antagonist and one approach to reversing opiate overdoses.  It is a commonly 
known medication that many doctors and paramedics have used during emergency cases after an 
opiate overdose and is the only FDA approved method of treatment for potential overdose 
(Substance Abuse and Mental Health Association [SAMHSA], 2020).  In some counties, the 
public can attend the training, which will teach them how to obtain and use Narcan.  In most 
states, Narcan can be purchased from any pharmacy without a prescription (Hodge, Gulinson & 
Barraza, 2019).  A decade ago, Narcan cost $1 for the single nasal spray (Hufford & Burke, 
2018).  The average cost today is $150 per dose of the nasal spray (Hufford & Burke, 2018).  
The Narcan auto-injector was approved in 2016 and cost $4,500 (Hufford & Burke, 2018).  
Pharmaceutical innovation is not the driving cost of Narcan, but opportunity is (Hufford & 
Burke, 2018).  Costs due to abuse of prescription opioids in the United States as of 2017 consist 
of $26 million in health care, along with $78.5 million in overall cost (Elflein, 2019).  One 
argument against Narcan use, is that it enables continued drug abuse (Elflein, 2019). However, 
other stakeholder interviews state that intervention may allow that person to live another day 
(Elflein, 2019).   
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1.2. Problem Statement 
 
The problem that we face as a nation is the increasing cases of opiate overdoses (CDC, 
2019).  Regulations vary across state lines regarding patient needs and prescribing regulations.  
The current study addresses closing the gaps in opioid use disorder. 
1.3. Research Questions  
 
The overarching research question for this study was -- How are Narcan policies related to 
the drug’s utilization?  In addition, the following sub questions were explored through analysis 
of national claims data: 
1. How do the characteristics of patients who receive a Narcan prescription differ across 
states that require a prescription and those that do not? 
2. Does the likelihood of receiving an opioid prescription differ between states that have a 
Narcan Access law?  
3. Does the dispensing of Narcan vary among states that require a prescription versus those 
that do not? 
1.4 Population 
The study population consisted of patients between the ages of 20 to 64 who have an 
insurance claim for the receipt of Narcan in 2016. This study examined the patient characteristics 







2    CHAPTER II SCOPING LITERATURE REVIEW 
This literature review synthesizes the current research and policy on the opioid epidemic in 
the United States. This chapter will cover factors driving the opioid epidemic, the impact of 
opioid use, and policy or medical treatment interventions.   
Factors driving the opioid epidemic 
 
In 1980, acute pain was predominantly treated with opioids which are narcotic pain relievers.  
They were the second-most dispensed drug within the United States at the time (Dasgupta, 
Beletsky & Ciccarone, 2018).   The Carter White House Administration stated, “Diversion, 
misuse, and abuse of legal drugs may be involved in as many as seven out of ten reports of drug-
related injury or death” (Dasgupta, Beletsky & Ciccarone, 2018).  A decade later, the US 
healthcare system was overcome by discoveries of lack of chronic pain treatment, motivating 
normative practice and policy shifts (Dasgupta, Beletsky & Ciccarone, 2018).  The Institute of 
Medicine attributed the increase in chronic pain management during the chronic pain 
pervasiveness during the 1990s to the following: (Dasgupta, Beletsky & Ciccarone, 2018).   
1. substantial patient expectations for pain relief, 
2. musculoskeletal disorders of the aging population, 
3. obesity, 
4. elevated survivorship post injury and cancer,  
5. rising frequency and complications of surgery. 
 
With behavioral pain therapy developing limited coverage, biopharmaceutical manufacturers 
considered this as an opportunity to formulate extended-release drugs, transdermal patches, nasal 
sprays, and oral dissolving strips (Dasgupta, Beletsky & Ciccarone, 2018).  Innovated pain-
modulating implants were also being driven by medical device manufacturers (Dasgupta, 
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Beletsky & Ciccarone, 2018).  By 2000, chronic pain became a big business in the medical 
industry (Dasgupta, Beletsky & Ciccarone, 2018).  Withdrawals became increasingly 
problematic in these nonopioid analgesics due to cardiovascular risk and acetaminophen toxicity 
heightened concerns about nonopioid alternatives (Dasgupta, Beletsky & Ciccarone, 2018).  It 
was common for pharmaceutical companies to market improperly by minimizing addiction 
potential for drugs such as OxyContin and promote off-label use of Actiq, later giving rise to 
physician kickback schemes, lucrative speaking fees, and lobbying (Dasgupta, Beletsky & 
Ciccarone, 2018).  A small proportion of physicians were dispensing opioids without adequate 
regard for medical needs (Dasgupta, Beletsky & Ciccarone, 2018).  These factors are believed to 
have contributed to the steady rise in opioid analgesic consumption over the past three decades, 
causing rates of overdose and addiction to increase (Dasgupta, Beletsky & Ciccarone, 2018).   
The second phase started around 2010, with a concern over intertwining of opioid 
analgesic and heroin use (Dasgupta, Beletsky & Ciccarone, 2018).  This remained stable for 
several years while heroin overdose deaths tripled between 2010 and 2015 (Dasgupta, Beletsky 
& Ciccarone, 2018).  There became an expanded pool of individuals with rising dependency and 
tolerance to opioid prescription drugs.  This led to these individuals transitioning to a more 
potent and cheaper alternative such as the reformulation of OxyContin (Dasgupta, Beletsky & 
Ciccarone, 2018).  During this phase, clinicians and policymakers reassessed the effectiveness 
and safety of outpatient use of opioid analgesics (Dasgupta, Beletsky & Ciccarone, 2018).   
The third phase developed in late 2013 and continues today (Dasgupta, Beletsky & 
Ciccarone, 2018).  There is an increasingly efficient global supply chains creating the emergence 
of potent and less bulky products such as illicitly manufactured fentanyl and its analogs, which 
are increasingly present in counterfeit pills and heroin (Dasgupta, Beletsky & Ciccarone, 2018).  
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Between 2013 and 2016, deaths related to fentanyl analogs spiked by a shocking 540% 
nationally (Dasgupta, Beletsky & Ciccarone, 2018).  This led to the declaration of as a national 
public health emergency placing blame on health care (Dasgupta, Beletsky & Ciccarone, 2018).   
Contradicting the blame placed on health care as the leading cause of addiction, individuals 
entering drug treatment facilities are now more likely to report having started opioid use with 
heroin, and not a specific prescription analgesic (Dasgupta, Beletsky & Ciccarone, 2018).    
As of 2017, a high percentage of adults in the U.S. contribute the opioid epidemic on the 
several scenarios (Elfein, 2017).  Survey respondents were able to select more than one 
contributing factor, leading to a complex set of issues to investigate.  79% of adults place 
majority of the blame on drug dealers selling opioid products.  Doctors overprescribing 
painkillers to patients comes in second with 76% of respondents considering this option as a 
contributing factor.  Individuals without prescriptions acquiring otherwise legal prescription 
medication make up 75%.   Most respondents also believe the pharmaceutical industry is 
encouraging doctors to prescribe opioids to their patients (72%).  Sixty-six percent of 
respondents stated patients demanding prescriptions to ease their pain as a contributing factor.  
The smallest category connected the opioid epidemic and the economic crisis of 2008 with 30% 
of respondents selecting this choice (Elfein, 2017). 
 Opioid anesthetics remain the most powerful drug class for controlling severe pain, but 
those medications have potential adverse effects, and pose a risk for misuse, and overdose (Rose, 
2018).   Poverty and substance abuse can influence the health framework that is extensively 
known to be significant in responding to public health challenges (Dasgupta, Beletsky & 




The evidence of chronic pain leading to drug overdose and suicide 
 Since 1999, age-specific mortality continues to rise from the trends in fatal drug overdose 
and suicide (Dasgupta, Beletsky & Ciccarone, 2018).  This trend is especially predominant 
among middle-aged White Americans without a college degree, who are now dying earlier, on 
average, than their parents (Dasgupta, Beletsky & Ciccarone, 2018).  Also, on-the-job injuries 
can contribute to the rise of chronically painful conditions, potentially resulting in a downward 
spiral of disability and poverty (Dasgupta, Beletsky & Ciccarone, 2018).  In the US, the counties 
with the lowest levels of social capital have the highest overdose rates (Dasgupta, Beletsky & 
Ciccarone, 2018).  Individuals with opioid dependence are likely to have interrupted opioid 
tolerance and a substantial elevation in overdose risk (Dasgupta, Beletsky & Ciccarone, 2018).  
In 2000, chronic pain was big business for pharmaceutical companies and medical device 
manufacturers (Dasgupta, Beletsky & Ciccarone, 2018).  In majority of the country, the counties 
with the lowest levels of social capital have the greatest overdose rates (Dasgupta, Beletsky & 
Ciccarone, 2018).  Individuals living in low socioeconomic communities were at greater risk to 
develop chronic pain after car crashes, a process mediated by stress response genes (Dasgupta, 
Beletsky & Ciccarone, 2018).   
Impact of the Opioid Epidemic 
Opioid Deaths 
 One of the greatest public health threats facing the United States today is the misuse of 
prescription and non-prescription opioids (Hershey, 2019).  In 2017, 70,237 opioid overdoses led 
to injury-related deaths (Hershey, 2019).  According to the U.S. Centers for Disease Control and 
Prevention (CDC), the prescription opioid deaths were five times higher in 2017 than reported in 
1999 (Hershey, 2019).   
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 The United States has experienced three distinct waves related to these deaths (Hershey, 
2019).  The first wave began in 1990s with the overprescribing of prescription medications 
(Hershey, 2019).  The second wave went into effect in 2010 with an increase of overdose deaths 
due to heroin (Hershey, 2019).  The final wave of 2013 occurred with the manufacturing of 



















Table 1: 2018 drug overdose death rate by state (per 100,000 population) (Elfein, 2020) 






























New Hampshire 35.8 
New Jersey 33.1 
New Mexico 26.7 
New York 18.4 
North Carolina 22.4 





Rhode Island 30.1 
South Carolina 22.6 












 Table 1 depicts the number of drug overdose deaths in the U.S. in 2018, by state (Elfein, 
2020).  There is considerable variation across the states, ranging from a low of 6.9 deaths per 
100,000 in South Dakota to 51.5 in West Virginia. Opioids are considered the primary 
prescription pain relievers, and heroin is the main driver of overdose deaths (Elfein, 2020). 
Health Policy and Treatment Interventions 
Emergency Deposition 
Various levels of the government announced the opioid crisis as a public health 
emergency, thereby supplying resources and avoiding undisclosed legal obstacles to response 
efforts (Hershey, 2019).  On October 26, 2017, President Trump advised Acting Secretary Eric 
Hargan of the Health and Human Services to declare the opioid crisis a national public health 
emergency (Hershey, 2019).  This declaration allowed the federal government to waive specific 
requirements for Medicaid coverage, supplying prescribing practices and training providers and 
advancing the National Institutes of Health research funding for treatment for opioid use disorder 
and overdoses (Hershey, 2019).  The United States Department of Health and Human Services 
developed a five-point comprehensive strategy: (1) better data, (2) better pain treatment, (3) 
more addiction prevention, treatment, and recovery services, (4) more overdose reversers, and 
(5) better research (CDC, 2019).   On July 17, 2019, the federal government renewed the public 
health emergency declaration (Hershey, 2019).   
Supervised Injection Facilities  
 Supervised Injection Facilities (SIF) are providing a harm-reduction strategy to 
preventing opioid-related overdoses and deaths (Hodge, Gulinson & Barraza, 2019).  This type 
of facility provides a safe environment for individuals to use illicit drugs in a clean environment 
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with immediate access to emergency medical services (Hodge, Gulinson & Barraza, 2019).  On 
February 7, 2019, The Department of Justice filed a lawsuit preventing SIF from opening a 
facility in Philadelphia, alleging multiple violations of the federal Controlled Substances Act 
(Hodge, Gulinson & Barraza, 2019).   
The evidence supporting Narcan use, versus other interventions 
 Narcan is an opioid antagonist approved in (1971) by the U.S. Food and Drug 
Administration (FDA).  Narcan reverses the effects of opioid overdose by displacing opioids 
from their receptors in the brain (Corso &Townley, 2016).  By blocking the effects of opioids on 
the brain, Narcan reverses respiratory depression caused by opioid overdose, which depreciates 
the possibility of overdose injury or death, including complications caused by non-fatal overdose 
such as brain and organ damage (Corso &Townley, 2016).  Unlike other interventions, Narcan 
can act quickly and immediately knocking opiate drugs off the receptors in the brain and 
reversing the effects of opiate overdose (“What Are the Key Differences Between Naltrexone 
and Naloxone?”, 2020).  This works best in particular issues where an individual has decreased 
heart rate and breathing rate (“What Are the Key Differences Between Naltrexone and 
Naloxone?”, 2020).  Narcan differs from other various treatments in a way that it is not designed 
to be used for long-term treatment of the abuse of opiate drugs, but instead it is commonly used 
as an emergency treatment for people who overdose on opiate drugs (“What Are The Key 
Differences Between Naltrexone And Naloxone?”, 2020).   
Various leading agencies and organizations, such as the Substance Abuse and Mental 
Health Services Administration (SAMHSA), CDC, the World Health Organization, the 
American Public Health Association, the American Medical Association, and the American 
Pharmacists Association recommend expanding access to Narcan as a key evidence-based 
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strategy to reduce opioid overdose injury and death (Corso &Townley, 2016).  Addiction 
services includes stages of treatment, along with detoxification, rehabilitation, and recovery 
(Corso &Townley, 2016).   
• Detoxification is a medical intervention that manages acute intoxication and withdrawal 
with the objective of minimizing physical harm.  This process can be broken down into 
three stages: patient evaluation and assessment, physical and psychosocial stabilization, 
and facilitating entry into treatment. 
• Rehabilitation (also referred to as treatment) incorporates ongoing primary medical and 
behavioral health care with ongoing assessments of the individual’s physical and 
psychosocial status as well as environmental risk factors. 
• Recovery (also referred to as maintenance) continues the behavioral health support 
present in the rehabilitation component of care and includes refining and fortifying 
strategies to encourage prevention against relapse. 
Medication-assisted treatment (MAT) incorporates the use of FDA-approved medications 
to assist individuals overcome alcohol or opioid dependence (Corso &Townley, 2016).  The 
FDA has approved three various medications for the treatment of opioid dependence: 
methadone, buprenorphine, and naltrexone (Corso &Townley, 2016).  The difference between 
the three types of medications is the way they interact with opioid receptors within the brain: 
(Corso &Townley, 2016).   
• Methadone is an opioid full agonist. It fully binds with the opioid receptors within the 
brain and serves as a replacement therapy for heroin or prescription opioids.  With 
creating tolerance, methadone treats symptoms of drug withdrawal and blocks euphoria.   
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• Buprenorphine is an opioid partial agonist.  Partial agonists produce comparable effects 
as a full agonist, but the effects are less inducive and involves a “ceiling effect” that 
predominantly increases the safety profile of the medication while reducing the risk of 
misuse or dependency. 
• Naltrexone, similar to naloxone, is an opioid antagonist.  Opioid antagonists inhibit 
opioid receptors within the brain, which means an individual using an opioid post taking 
naltrexone will not feel the opioid’s effects. 
 




 Narcan may precipitate sudden opioid withdrawal in physically dependent individuals; 
signs and symptoms may include body aches, fever, sweating, sneezing, yawning, nausea, 
vomiting, sweating, lacrimation, rhinorrhea, cramping, insomnia, chills/hot flashes, piloerection, 
tachycardia, anxiety, restlessness, irritability, tremulousness, hypertension, seizures, and cardiac 
arrest (Narcan Nasal Spray Side Effects, 2019).  With the use of Narcan nasal spray, nasal 
dryness, nasal edema, nasal congestion, and nasal inflammation were common adverse reactions 
that were reported (Narcan Nasal Spray Side Effects, 2019). 
Policy and Narcan Overdose Prevention Laws 
 State lawmakers are developing innovative policies-engaging health, criminal justice, 
human services, and other sectors- to address the public health crisis while also providing 
appropriate access to pain management (NCSL, 2019).  The access to Narcan can be limited by 
state laws and regulations (“Preventing Opioid Overdoses Among Rural Americans”, 2018).   
State laws and regulations have a direct influence on the availability of overdose reversing 
medicines.  Currently, the changing laws continue to increase the access to naloxone in all fifty 
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states and the District of Columbia.  All states have legislation designed to enhance layperson 
Narcan access, along with protections for health care providers who prescribe or dispense Narcan 
and for bystanders who administer the drug.  The Good Samaritan laws were passed on July 15, 
2017, within 40 states and the District of Columbia that protects bystanders who report 
overdoses from facing their own possible drug possession charges (“Preventing Opioid 
Overdoses Among Rural Americans”, 2018).    
 Legislation limited opioid prescriptions in the early 2016, with Massachusetts passing the 
first law in the nation (National Conference of State Legislatures {NCSL}, 2019).  
Massachusetts set a seven-day supply limit for initial (first-time) opioid prescriptions.  By the 
end of 2016, seven states also passed legislation reducing opioid prescriptions, and the 
movement continued in 2017.  More than 30 states expressed over 130 bills related to opioid 
prescribing in 2016 and 2017.  According to NCSL’s tracking, 33 states had executed legislation 
with limitations, guidance or requirements related to opioid prescribing by October 2018 (NCSL, 
2019).   
 Some state laws allow doctors to provide Narcan to any person who could administer the 
drug to another person who is at risk for an overdose, also known as third-party prescriptions 
(“Preventing Opioid Overdoses Among Rural Americans”, 2018).  Evidence shows that 
educating family and/or close friends about the warning signs of overdose and the ability to use 
Narcan to help the prevention of overdose (“Preventing Opioid Overdoses Among Rural 
Americans”, 2018).   
 State laws and regulations determine whether all emergency personnel can administer 
Narcan to patients (“Preventing Opioid Overdoses Among Rural Americans”, 2018).  With the 
various levels of training for emergency personnel, and emergency medical technicians in rural 
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areas, they are more likely to be trained to provide only basic-level life support (“Preventing 
Opioid Overdoses Among Rural Americans”, 2018).  This practice law determines which 
emergency personnel can administer Narcan (“Preventing Opioid Overdoses Among Rural 
Americans”, 2018).    
 Senate Enrolled Act 406-2015, “Aaron’s Law”, was signed into law April 2015.  This 
Indiana law allows citizens to obtain a prescription for Narcan if they believe someone they 
know is at risk of an opioid overdose (Indiana Department of Labor [Indiana], 2020).  Aaron’s 
Law allows Narcan to be available to on-site medical staff, school nurses, supervisors, and 
anyone responsible for someone at risk of an overdose (Indiana Department of Labor, 2020).  
Aaron Sims was a young man who lost his battle with a heroin addiction (Indiana Department of 
Labor, 2020) and the Senate Enrolled Act 406-2015, “Aaron’s Law” was named after Sims 
(Indiana, 2020).   
 Most of the legislation limits first-time opioid prescriptions to a determined number of 
days’ supply, seven days is most common, with some laws set limits at three, five or 14 days 
(NCSL, 2019).  Almost half of the states with limits specify that they apply to treatment of acute 
pain, and most states set exceptions for chronic pain treatment (NCSL, 2019).  Most of the states 
focus on general opioid prescribing; Alaska, Connecticut, Indiana, Louisiana, Massachusetts, 
Nebraska, Pennsylvania, and West Virginia also set limits for minors (NCSL, 2019).  These laws 
set limits for any opioid prescription (versus the initial opioid prescription for adults) and may 
also identify various requirements, including discussing opioid risks with the minor and parent or 
guardian (NCSL, 2019). 
 Instead of setting opioid prescription limits in statute, several state laws directed or 
authorized other entities to do so (such as New Hampshire, Ohio, Oregon, Vermont, Virginia, 
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Washington, and Wisconsin) (NCSL, 2019).  These entities consist of the department of 
health/state health/state health official, or provider regulatory boards such as the board of 
medicine, nursing and/or dentistry (NCSL, 2019).  Rhode Island and Utah have prescribing 
limits in statute and allowing other entities to adopt prescribing policies (NCSL, 2019).   
 State leaders continue to tackle prescription drug misuse with various approaches (NCSL, 
2019).  While attempting to avert or intervene earlier in misuse, addiction and overdose, states 
have established various laws regarding prescription drug monitoring programs, access to 
Narcan, pain clinic regulation, provider education and training (NCSL, 2019).  NCSL tracks 
these bills in the Injury Prevention Database, which shadows six categories of legislation aimed 
at preventing prescription opioid misuse (NCSL, 2019). 
The government from different levels disclosed the opioid crisis as a public health 
emergency, allowing various resources available across state lines in efforts to reduce opioid 
related deaths (Hersey, 2019).  There are numerous contributing factors throughout this period 
that places blame on the opioid epidemic.  Controlling severe pain is one main purpose for the 
dispensing of an opioid anesthetic.  With this type of controlled substance other health concerns 
develop such as adverse effects which leads to misuse and overdose (Rose, 2018). 
A vast majority of legislation has applied limits on controlled substances to prohibit the 
ability overdose and addiction.  Changes in access laws pertaining to Narcan vary in every state 
throughout the years.  In 2015, six times greater opioids per resident were dispensed in the 
highest-prescribing counties than in the lowest-prescribing counties (Centers for Disease Control 
and Prevention, 2017).  County-level characteristics, such as rural versus urban, income level, 
and demographics, are only a third of the differences (Centers for Disease Control and 
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Prevention, 2017).  It is common that patients receive different care depending on where they 
live.  Characteristics of counties with greater opioid prescribing consist of the following: 
• Small cities or large towns 
• Higher percent of white residents 
• More dentists and primary care physicians 
• More people who are uninsured or unemployed 
















    CHAPTER III METHODOLOGY 
3.1 Research Design 
 A descriptive study was conducted to explore how state-level Narcan policies are related 
to the drug’s utilization.  The following sub questions were explored through analysis of national 
claims data: 
1. How do the characteristics of patients who receive a Narcan prescription differ across 
states that require a prescription and those that do not? 
 
2. Does the likelihood of receiving an opioid prescription differ between states that have a    
Narcan Access law? 
 
3. Does the dispensing of Narcan vary among states that require a prescription versus those 
that do not? 
 
3.2 Sample Selection 
The data sample included 3,756,833 prescriptions from 1.6 million privately insured 
individuals between the ages of 20 to 64 who have an insurance claim for the receipt of and 
opioid drug and/or Narcan in 2016. 
3.3 Data Set Description 
This study uses a sample of retrospective claims for patients with opioid prescriptions 
and naloxone dispensing from an original study by Dr. Kit Simpson (unpublished data). The 
retrospective claims analysis utilized data from the Truven Health MarketScan Commercial 
Database in the calendar year 2016. This data includes Narcan prescriptions and patient 
demographics for all 50 states.  This MarketScan Commercial Database includes patient claims 
from states that do not have a Narcan access law and states with a Narcan access law.  




3.4 Data Analysis 
Data were extracted from public data sources on laws and regulations in place for 
dispensing Narcan. We elected to use the year 2016 because that year marked a major change 
nationally in recognition of opioid as a major epidemic problem. For each time, period patient 
claims were coded as 0 if the state does not have a Narcan access law, and 1 for states with a 
Narcan access law (Table 3). The analysis compared the number of Narcan prescriptions across 
states with and without Narcan access laws. Descriptive comparisons between the Access Law 
Group and Non-Access Law was conducted using t-tests for normally distributed continuous 
variables and Chi Squared Tests or Fishers Exact Test for Categorical Variables, as appropriate. 
Key outcomes include: Narcan prescriptions filled for patients that live in access law states, 
Opioid prescriptions for patients that live in access law states, and characteristics of patients who 
receive a Narcan or opioid prescription.  The data covers individuals from various geographic 






























to other entity to set 
limits or guidelines 
No 
Limit 
Alabama No No No No No No Yes 
Alaska No No No No No No No 
Arkansas No Yes No No No No No 
Arizona No No Yes No Yes No No 
California No No No No No No Yes 
Colorado No Yes No No No No No 
Connecticut No Yes No No No No No 
Delaware No No No No No No Yes 
District of Columbia No No No No No No No 
Florida No No No Yes No No No 
Georgia No No No No No No Yes 
Hawaii No Yes No No No No No 
Idaho No No No No No No Yes 
Illinois No No No No No No Yes 
Indiana No Yes No No No No No 
Iowa No No No No No No Yes 
Kansas No No No No No No Yes 
Kentucky No No No Yes No No No 
Louisiana No Yes No No No No No 
Maine No Yes No No Yes No No 
Maryland No No No No No No Yes 
Massachusetts No Yes No No No No No 
Michigan No No No No No No Yes 
Minnesota No No No Yes No No No 
Mississippi No No No No No No Yes 
Missouri No Yes No No No No No 
Montana No Yes No No No No No 
Nebraska No No No No No No Yes 
Nevada Yes No No No Yes No No 
New Hampshire No No No No No Yes No 
New Jersey No No Yes No No No No 
New Mexico No No No No No No Yes 
New York No Yes No No No No No 
North Carolina No No Yes No No No No 
North Dakota No No No No No No Yes 
Ohio No No No No No Yes No 
Oklahoma No Yes No No No No No 
Oregon No No No No No Yes No 
Pennsylvania No Yes No No No No No 
Rhode Island No No No No Yes Yes No 
South Carolina No Yes No No No No No 
South Dakota No No No No No No Yes 
Tennessee No No No Yes Yes No No 
Texas No No No No No No Yes 
Utah No Yes No No No Yes No 
Vermont No No No No No Yes No 
Virginia No No No No No Yes No 
Washington No No No No No Yes No 
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West Virginia No Yes No No No No No 
Wisconsin No No No No No Yes No 
Wyoming No No No No No No Yes 
 
 
Table 2 illustrates the state’s primary opioid prescription limit and does not include additional 
limits on certain providers or in certain setting (NCSL, 2019).  Most of the legislation limits first-
time opioid prescriptions to a certain number of days’ supply- seven days is most common, with 



























Table 3: States with Narcan Access Laws by Year (2015-2017) (Source: Naloxone Overdose, 2017) 
State 2015 2016 2017 
Alabama No Yes Yes 
Alaska No No Yes 
Arkansas No No Yes 
Arizona No Yes Yes 
California Yes Yes Yes 
Colorado Yes Yes Yes 
Connecticut Yes Yes Yes 
Delaware Yes Yes Yes 
District of Columbia Yes Yes Yes 
Florida No Yes Yes 
Georgia Yes Yes Yes 
Hawaii No No Yes 
Idaho No Yes Yes 
Illinois Yes Yes Yes 
Indiana No Yes Yes 
Iowa No No Yes 
Kansas No No Yes 
Kentucky Yes Yes Yes 
Louisiana No Yes Yes 
Maine Yes Yes Yes 
Maryland Yes Yes Yes 
Massachusetts Yes Yes Yes 
Michigan Yes Yes Yes 
Minnesota Yes Yes Yes 
Mississippi No Yes Yes 
Missouri No No Yes 
Montana No No Yes 
Nebraska No Yes Yes 
Nevada No Yes Yes 
New Hampshire No Yes Yes 
New Jersey Yes Yes Yes 
New Mexico Yes Yes Yes 
New York Yes Yes Yes 
North Carolina Yes Yes Yes 
North Dakota No Yes Yes 
Ohio Yes Yes Yes 
Oklahoma Yes Yes Yes 
Oregon Yes Yes Yes 
Pennsylvania Yes Yes Yes 
Rhode Island Yes Yes Yes 
South Carolina No Yes Yes 
South Dakota No No Yes 
Tennessee Yes Yes Yes 
Texas No Yes Yes 
Utah Yes Yes Yes 
Vermont Yes Yes Yes 
Virginia Yes Yes Yes 
Washington Yes Yes Yes 
West Virginia No Yes Yes 
Wisconsin Yes Yes Yes 




All jurisdictions now have laws that address accessibly to Narcan for individuals at risk 
of opiate overdose (Naloxone Overdose Prevention, 2017).  These laws allow distribution 
beyond the traditional prescriptions (Preventing the Consequences of Opioid Overdose: 
Understanding Naloxone Access Laws, 2018).  This allows individuals to obtain Narcan with 
flexibility (Preventing the Consequences of Opioid Overdose: Understanding Naloxone Access 
Laws, 2018).  Table 3 illustrates the changes in access laws regarding Narcan within every state 
through the years of 2015-2017.  Starting in 2015 there were more jurisdictions that did not have 
Narcan access laws.  The following year in 2016 more jurisdictions came onboard implementing 
the new law.  By 2017, every state set into motion the Narcan access law.  This was a major 
turning point for the country. 
Protection of Human Subjects 
 This study was classified as non-human subjects by the Medical University of South 










CHAPTER IV RESULTS 
 This study was a retrospective review of data sets constructed for a previous study of 
opioid use. The data were originally obtained from Truven Health MarketScan Commercial 
Database from January through December 2016. This study examined how state-level Narcan 
policies are related to the drug’s utilization.  The data sample included 3,756,833 prescriptions 
from privately insured individuals between the ages of 20 to 64 who have an insurance claim for 
the receipt of and opioid drug and/or Narcan in 2016.  The Statistical Package for Social 
Sciences (SPSS) version 24 was used to analyze the data. 
The study included a total of 3,756,833 prescriptions. Of these, 14,210 (0.38%) were for 
naloxone and opioids, 1,660 (0.04%) for naloxone only, and 3,740,963 were for opioids only 
(99.6%). Data were extracted from prescriptions provided to 1.6 million privately insured 
individuals in 2016 (Table 4).  There was a statistically significant difference (p=<.0001) in the 
mean age of those receiving a prescription for Naloxone & Opioids (49.3) versus Naloxone Only 
(43.7) or Opioids Only (42.6).  
Table 4. Age, Sex and Payments for 3,756,833 Prescription Records from Privately Insured 
Individuals with one or more prescriptions for Naloxone and/or opioids in 2016  







Age Mean ± SD 49.3 ± 10.9 43.7 ± 14.5 42.6 ± 14.8 <0.0001 
Female Sex N 
(%) 8,675 (61.0) 1,000 (60.2) 2,174,401 (58.1) 
<0.0001 
 
 The mean prescription copayment for Naloxone and Opioids (14,210, 0.38%) was $37 
(SD $143) versus $43 (SD $275) for Naloxone only (1,660, 0.04%) (Table 5).  The mean 
ingredient cost is higher for Naloxone and Opioids ($1,060 + 1,782) versus Naloxone only ($997 
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+ 1,847).  The payment means and standard deviations were similar to ingredient cost at $1,061+ 
1,783 for Naloxone and Opioids and $989 + 1,839 for Naloxone only (Table 5). 
Table 5: Cost and Copays of 3,756,833 Privately Insured Individuals with one or more 
prescriptions for Naloxone and/or opioids in 2016 
Naloxone Cost 
Variables in Dollars 








Copay Mean ± SD $37 ± 143 $43 ± 275 NA  
Ingredient Cost  
Mean ± SD 
$1,060 ± 1,782 $997 ± 1,847 NA  
Payment Mean ± SD $1,061 ± 1,783 $989 ± 1,839 NA  
 
Table 6: 2016 Individuals with Opioid and Naloxone Prescriptions by State Policy Status 











350 (5.2%) 6363 (94.8%) 6713 p<0.0001 
 
In total, 6713 individuals with opioid prescriptions were also dispensed Naloxone across 
the United States in 2016 (p<0.0001) (Table 6).  There is a statistically significant difference in 
the number of prescriptions between states with and without the Narcan access law (p<0.0001). 
Approximately 94.8% of the prescriptions for Opioids and Naloxone were dispensed in states 
with the Narcan Access Law, while only 5.2% of the prescriptions were dispensed in states 






Table 7: Likelihood of patients having prescriptions for both Opioid and Naloxone Prescription in 
Access Law States, adjusting for a state, rate of overdoses, and patient sex, age, and rural residence 
 Odds 95% CI P Value 
Access Law 1.33 1.194-1.482 p<0.0001 
Overdose Death 0.986 0.983-0.989 p<0.0001 
Age 1.034 1.032-1.036 p<0.0001 
Sex (Male) 0.842 0.802-0.885 p<0.0001 
Rural 0.790 0.732-0.853 p<0.0001 
 
Patients with an Opioid prescription who live in an Access Law state are 33% more likely 
to receive Naloxone than patients in states without this legislation. However, for all patients in 
the data set, patients in states with high overdoes are 1.4% less likely to get Naloxone, as are 
male and those living in the rural area of the state.  However, older patients are more likely to get 
a Naloxone prescription, with 3% times higher odds of Naloxone per year increase in age. 
Table 8: 2016 Naloxone Prescriptions by State Policy Status 









370 (5%) 7078 (95%) 7448 p<0.0001 
 
In total, 7448 Naloxone prescriptions were dispensed in 2016 (p<0.0001) (Table 8). 
Approximately 5% of the Naloxone prescriptions were dispensed in states without the Narcan 
Access Law.  The states with Narcan Access Law delivered 95% of the Naloxone prescriptions 
which were dispensed without regards to opioid prescriptions. 
Table 9 Odds Ratio of a Naloxone Prescription in Access Law States 
 Odds 95% CI P Value 
Access Law 1.400 1.26-1.555 p<0.0001 
Overdose Death 0.989 0.985-0.992 p<0.0001 
Age 1.030 1.028-1.032 p<0.0001 
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Sex (Male) 0.850 0.811-0.890 p<0.0001 
Rural 0.819 0.762-0.880 p<0.0001 
 
The odds of receiving a Naloxone prescription in Access Law states were 40% greater 
than the states without the Access Law in 2016 (Table 9) (p<0.0001).  This relationship was 
observed after we controlled for factors, such as a state’s rate of opioid overdoses, and patient 
demographics, including age, sex, and rural residence. The overdose odds of receiving Naloxone 
was 1.1% lower in for states with higher rates of opioid overdoses.  Across all states, patient age 
increases the likelihood of receiving Naloxone (OR 1.03).  Males have 15% lower odds of a 
Naloxone prescription.  Patients living in rural areas of the country have a 18.1% lower 













Chapter V Discussion 
This study revealed various important findings, signifying the influence of state Narcan 
Access Laws on the dispensing of Naloxone and on Opioid-related deaths.  In 2016, less than 1% 
of the study population received a prescription for Naloxone and Opioids or Naloxone only 
(Table 4). Of the 3,756,833 Opioid prescriptions dispensed, 15,870 Naloxone prescriptions were 
dispensed.  Of the 15,870 Naloxone prescriptions dispensed, 95% were in states with a Narcan 
Access Law. Those living in a state with a Narcan Access Law were 33% more likely to receive 
a Naloxone prescription, as were those who were older and female.  Additionally, the cost of 
copays for Naloxone and Opioids was less expensive than the copay for Naloxone alone.  When 
examining individuals with an opioid prescription, there were an extremely low number who also 
had a Naloxone prescription. However, there was a 40% greater chance of receiving a 
prescription for Naloxone only in states with the Narcan Access Law.  Those residing in rural 
areas of the country had 18.1% lower odds receiving a prescription for Naloxone only.    
Limitations 
 This research is subject to several limitations.  The data were collected from insurance 
claims data, hence the potential for errors in coding.  We were unable to account for differences 
across state that may also impact Naloxone prescriptions that were not related to patient 
characteristics or the Narcan Access laws, such as stigma. Finally, the study examines patients 
age 20-64 with commercial insurance. Results may not be generalizable to other ages or payer 





Policy and Research Implications 
There are many factors that contribute to rising overdose rates. Previous studies have 
shown a rise in opioid analgesic and heroin use and overdose (Dasgupta, Beletsky & Ciccarone, 
2018).  In 2016 deaths related to fentanyl analogs spiked by a shocking 540% nationally 
(Dasgupta, Beletsky & Ciccarone, 2018).  Also, previous studies illustrate that counties with the 
lowest levels of social capital have the greatest overdose rates (Dasgupta, Beletsky & Ciccarone, 
2018).  As elucidated in this study, states with higher rates of Opioid overdoses had lower odds 
of receiving lifesaving Narcan, and those residing in rural areas had decreased odds of receiving 
a Naloxone prescription.  Due to these findings, policy makers should consider laws to increase 
awareness and education regarding Opioid-use disorder and provide access to supportive 
services, including Naloxone (Faul, Dailey, Sugerman, Sasser, Levy & Paulozzi, 2015).  
While Narcan access policies differ across states, it is unclear which policy components 
are most helpful in improving access to Naloxone. Future research should examine the 
differences in Narcan Access Laws across states to examine if specific policy interventions are 
more effective.  Research should also focus on disparities amongst states and rural residence to 
ensure consistency in adherence to best practices regarding the treatment of opioid use disorder.  
Further, across all states, male patients and those living in rural communities are less likely to get 
Narcan prescriptions filled. Future policy work should examine access to Narcan prescriptions 







 In the last two decades, there has been a rise in misuse of prescription and illicit opioids 
(Hodge, Gulinson & Barraza, 2019).  During this time, across the United States, there has been 
an increase in Opioid-induced and Opioid-related deaths (Centers for Disease and Control and 
Prevention [CDC], 2019).  We are presently facing an Opioid-use Disorder (OUD) with high 
rates of deaths from opioid overdoses. The treatment of OUD is complex but the prevention of 
deaths from opioid overdoses is relatively simple even for lay individuals if they have access to 
naloxone (Narcan) a drug that reverses opioid overdoses. Narcan is an opioid antagonist 
approved in (1971) by the U.S. Food and Drug Administration (FDA).  Narcan reverses the 
effects of opioid overdose by displacing opioids from their receptors in the brain (Corso 
&Townley, 2016). Leading agencies, such as the Substance Abuse and Mental Health Services 
Administration (SAMHSA), CDC, the World Health Organization, the American Public Health 
Association, the American Medical Association, and the American Pharmacists Association 
recommend expanding access to Narcan as a key evidence-based strategy to reduce opioid 
overdose injury and death (Corso &Townley, 2016). However, access to Narcan can be limited 
by state laws and regulations (“Preventing Opioid Overdoses Among Rural Americans”, 2018).  
The availability of naloxone differs greatly across the fifty states. Results of this study 
indicate that Narcan policies are related to the drug’s utilization, as commercially insured 
patients who lived in states with Narcan Access Laws were more likely to receive a Naloxone 
prescription. States with higher rates of deaths from opioid overdoses had lower likelihood of 
having Narcan dispensed. The characteristics of patients who receive a Narcan prescription differ 
in both age and rural residence compared to those who do not.  Being male or living in a rural 
area was associated with decreased odds of receiving a Naloxone prescription.  
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Results of this study also indicate that Narcan Access Laws are associated with 
differences in prescribing behaviors. Thus, access to the life-saving medicine is not equal across 
states in the U.S. Few studies have been conducted with specific focus on the opioid epidemic 
across state lines and spanning decades.  What we have learned through this and prior studies is 
that the opioid epidemic has continuously advanced over the years. While the effect is modest, 
there appears to be a relationship between Narcan Access laws, increased Narcan prescriptions, 
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Age Mean ± SD 49.3 ± 10.9 43.7 ± 14.5 42.6 ± 14.8 <0.0001 
Female Sex N 
(%) 
8,675 (61.0) 1,000 (60.2) 2,174,401 (58.1) <0.0001 
  
Naloxone Cost 
Variables in Dollars 








Copay Mean ± SD $37 ± 143 $43 ± 275 NA  
Ingredient Cost  
Mean ± SD 
$1,060 ± 1,782 $997 ± 1,847 NA  
Payment Mean ± SD $1,061 ± 1,783 $989 ± 1,839 NA  
 









350 (5.2%) 6363 (94.8%) 6713 p<0.0001 
 
 Odds 95% CI P Value 
Access Law 1.33 1.194-1.482 p<0.0001 
Overdose Death 0.986 0.983-0.989 p<0.0001 
Age 1.034 1.032-1.036 p<0.0001 
Sex (Male) 0.842 0.802-0.885 p<0.0001 
Rural 0.790 0.732-0.853 p<0.0001 
 









370 (5%) 7078 (95%) 7448 p<0.0001 







 Odds 95% CI P Value 
Access Law 1.400 1.26-1.555 p<0.0001 
Overdose Death 0.989 0.985-0.992 p<0.0001 
Age 1.030 1.028-1.032 p<0.0001 
Sex (Male) 0.850 0.811-0.890 p<0.0001 
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